Bill Cheliak, Chairman

Dr. Cheliak is the CEO of Panag Pharma, a Canadian biotech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of business experience in a wide variety of biotechnology fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. In addition to having held executive positions in the public sector, he has extensive deal-making experience within the pharmaceutical industry, academic institutions and research hospitals including securing financing with both big and small pharma. He currently serves as a Director of Solarvest (SVS) and is Vice Chair of the Government of Canada’s Networks Centres of Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee providing advice and recommendations to the Government of Canada on funding of large national science and infrastructure initiatives. Dr. Cheliak has a Ph.D. in Genetics from the University of Alberta.

Gregory Drohan , Director

Until 2013, Greg Drohan served as President of the Board of Church and Dwight Canada Corp. While there, Drohan successfully merged the Church & Dwight and Carter-Horner businesses which led to the doubling of sales revenue and achieved #1 market share on brands such as Trojans, Oxi Clean, First Response, Rub A535 and Arm & Hammer. Following his successful 40-year career in the consumer products sector Mr. Drohan has established a management consulting practice. In addition to his board role at Church and Dwight, he also served as Director of the Ryerson University Alumni Relations Board. Drohan holds an MBA from York University and a BBM from Ryerson Polytechnical Institute.

Carl Merton , Director

Mr. Merton has over 20 years of financial and business experience, including 10 years as CFO for public companies involved in the capital markets. Following 12 years with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance specialist. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. Since assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In this role, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”).